• By bringing together data from across the region, we show that influenza contributes to the public health burden in Asia-Pacific countries, with a variable, but substantial proportion due to influenza B. Influenza vaccination policies are needed in Asia-Pacific countries, and the use of quadrivalent influenza vaccines could provide additional benefits.
specific high-risk groups prioritized by WHO for vaccination include pregnant women, the highest priority group, followed by individuals with a compromised immune system and individuals with comorbidities such as pulmonary or cardiac disease. in up to 60% of samples in Europe during the same period, with a seasonal average of 24% and 23% of samples, respectively. 7 Seasonal influenza vaccines are modified annually to include those antigenic variants that are likely to predominate in the following influenza season. Vaccine strain selection is performed by the WHO using data from the Global Influenza Surveillance and Response System, a network of over 140 institutions in 111 countries. 8 The B/Yamagata and B/Victoria influenza strains are antigenically distinct, and vaccines using one lineage induce only low levels of cross-protection to the other lineage. 9, 10 Trivalent seasonal influenza vaccines only contain one influenza B lineage, and it is not always possible to predict which B lineage will predominate during the next influenza season. 11 Mismatch between the vaccine lineage and circulating influenza B lineage has occurred regularly, which can have a significant impact on influenza vaccine efficacy. 4, [12] [13] [14] Since 2012, the WHO has recommended the inclusion of strains from both B lineages in quadrivalent seasonal influenza vaccines. 15 Co-circulation of both influenza type B lineages has also been documented throughout South-East Asia and Oceania. 5 The use of influenza vaccine in many Asia-Pacific countries is limited, and the potential impact of quadrivalent influenza vaccines on illness and hospitalization rates in these countries is not known, but is also likely to be low. 16 To obtain an epidemiological view of influenza type B in the Asia-Pacific region, we conducted a review of the available literature.
We attempted to identify periods of influenza B lineage mismatch between vaccine and circulating strains in 15 countries within the Asia-Pacific region to better inform health authorities of the potential benefits of quadrivalent influenza vaccines for protection against seasonal influenza.
| METHODS
Fifteen countries were selected from within the Asia-Pacific region traversing all climatic zones ( Figure 1 ). These included Northern 
| Search strategy and selection criteria
Articles were identified from PubMed and the Western Pacific Region Index Medicus (WPRIM) using search strings comprised of terms that identified influenza, the selected countries of interest in the Asia-Pacific region, and the epidemiology/burden of disease (Appendix S1). The search covered publication dates between January 1990 until 11 April 2016 and was limited to articles published in English language. Titles and abstracts were screened for relevance: That is, reported outcomes related to seasonal influenza in humans and in a country of interest. Articles were excluded if they reported pharmacokinetic or pharmacodynamic studies, case reports, case series, clinical trials, or meta-analyses. Articles were also excluded if they reported features of influenza pathophysiology, treatment, or diagnosis, or if they reported data in fewer than 30 patients. Publications without abstracts were only reviewed if the title fitted the review objectives. Full-text articles were reviewed to assess their relevance and methodological quality. Articles were excluded if the method sections were insufficiently described; if the content did not provide relevant information to the review objectives; if the article reported "pneumonia and influenza" as a combined outcome (unless pneumonia was described as a complication of influenza), outcomes from mathematical models; and if no quantitative data could be retrieved. Gray literature including WHO websites, local ministries of health, and WHO vaccine recommendations was also assessed for relevance. Extracted data included information on epidemiology and circulating strains. We did not collect clinical criteria or clinical case definitions of influenza, influenza-like illness (ILI), febrile illness, acute respiratory infection (ARI) disease, or severe acute respiratory illness (SARI) used in individual studies. Nor did we specify the methods for selecting cases for specimen collection or the influenza-testing method used for laboratory diagnosis. In our review, "laboratory-confirmed influenza" or a "positive sample" refers to a case of influenza confirmed by the method stated in the reporting paper.
An influenza B mismatch was defined as the circulating influenza B virus lineage strains differing from the B lineage representative strain included in the WHO-recommended influenza vaccine composition for that season. When <20% of the circulating influenza B strains differed from the WHO-recommended vaccine strain, we arbitrarily considered the degree of mismatch to be "low." A difference between 20% and 40% was considered as partial mismatch. We considered a significant mismatch as >40% and complete mismatch when ≥95% of the circulating influenza B lineage strains did not belong to the trivalent vaccine lineage.
The initial literature search in 2013 was conducted by Pallas Health
Research and Consultancy B.V., the Netherlands. Quality control activities included review of the first 30% of titles and abstracts and of the first 10% of full-text articles in duplicate by two independent researchers from Pallas. Any disagreements were adjudicated by a third researcher. The search was updated in 2016 by BM, and the articles were selected by BM and JC.
Ethics approval was not required for this study. The majority of relevant publications concerned surveillance or other observational epidemiological studies for which no standard quality checklists are currently available.
| RESULTS
There were 121 English language articles included in the review (Figure 2 ), of which 120 articles provided information on influenza B strains as a proportion of all laboratory-confirmed influenza from data collected between 1990 and 2015 (Table 1) . Most assessed specific, but diverse, populations of interest, such as patients T A B L E 1 (Continued) (Continues) hospitalized for respiratory tract infections (RTI), patients in intensive care, and respiratory samples from in/outpatients with a broad range of underlying respiratory syndromes. In many studies, the age range of subjects/samples was not specified. Many studies included patients with diagnoses of low specificity for influenza such as "febrile illness," "ILI," and "acute lower respiratory tract infection" (ALRTI). There were 102 prospective studies (two studies included both prospective and retrospective components). Sample sizes in individual study groups ranged from 26 to more than 300 000.
| Influenza surveillance and vaccine coverage in Asia-Pacific countries
With the exception of Myanmar, all of the countries studied use a sentinel site approach for influenza surveillance ( T A B L E 1 (Continued) influenza vaccine; in 2015, 62% of circulating influenza viruses were type B with a partial (36%) mismatch to the trivalent vaccine influenza B component (Table 3) . [20] [21] [22] We identified 18 articles that described influenza B 26, 27 Comparing to these two studies, another study encompassing the same study period reported a much lower influenza B proportion among hospitalized children with laboratory-confirmed influenza (2.5%).
28
In 2012, GP clinic-based surveillance in Western Australia and Victoria reported similar influenza detection rate among ILI patients. 29, 30 The proportion of influenza B among influenza-positive samples obtained from ILI patients was significantly higher in Western Australia than in Victoria (43% vs 13.6%).
| Cambodia
Since H1N1/pdm09. 36 The 2010 influenza B peak was also reported in studies conducted in northern, central, and eastern part of China. [37] [38] [39] [40] A study conducted in central China assessed SARI hospitalizations by type of influenza and found that in 2010-11, A (H3N2) virus was associated with a higher SARI hospitalization rate (55/100 000) than both influenza B and A (H1N1)pdm2009. In the following year, the incidence of SARI hospitalization was highest with influenza B (98/100 000). 
| Indonesia
We identified five articles with data relevant to Indonesia ( Table 2) .
Three of these papers were based on ILI surveillance of multiple seasons, reporting a proportion of type B viruses between 25.4% and 36% among all influenza-positive samples during the overall study period. 34, 42, 43 Two papers provided season-specific information on the proportion of influenza B among all ILI cases with laboratoryconfirmed influenza in 2010-11 and 2011-12. 44, 45 One of them also provided data in SARI patients with laboratory-confirmed influenza in 2011-12. In that study, the influenza detection rate was higher among ILI than among SARI patients (34.5% vs 15.4%). In both patient groups, 47% of laboratory-confirmed influenza cases were influenza B. 
| Myanmar
Three 
| New Zealand
Seven articles describing influenza in New Zealand between 1990 and 2015 were identified. National influenza surveillance data showed that during 1997-2008, on average 718 cases of laboratory-confirmed influenza were detected every year. 53 Influenza surveillance in 2005 recorded the highest influenza B activity since 1990 with co-circulation of influenza strains from B/Victoria and B/Yamagata lineages, which resulted in significant B strain mismatch with the recommended vaccine composition. 54 In 2015, 44.2% of patients with ILI and 23.6% SARI patients tested positive for influenza. 55 The proportion of influenza B among all influenza-positive samples was 13%, but half of them mismatched the B strain contained in the influenza vaccines for that season (Table 3) .
| Papua New Guinea
In the one study identified as providing information on influenza in Papua New Guinea, 29.3% of samples from patients with ILI received by the Papua New Guinea National Influenza Centre in 2010 had laboratory-confirmed influenza, of which 43.2% were influenza type B. 
| Singapore
In Singapore, the National Influenza Centre carries out influenza virus surveillance using samples from public hospitals and sentinel clinics. 62 Ten articles reporting data in Singapore from 1990 until 2012 were identified ( Table 2) 
| South Korea
Eleven articles reported the distribution of influenza A and B viruses in South Korea between 1990 and 2013 (Table 2) . Six studies were conducted in hospital emergency or outpatient departments, one included hospitalized children, one included adults in the intensive care unit (ICU), and three studies reported laboratory surveillance.
Between 2007 and 2015, the Korean Influenza Surveillance System reported three influenza seasons with around 50% or higher proportion of influenza B; all three seasons had B lineage mismatch of >20% (Table 3 ). The highest percentage of influenza B positive samples was reported in a retrospective laboratory-based study in which 43.4% of children and 55.8% of adults with laboratoryconfirmed influenza had type B. 69 The study period encompassed the 2007-08 influenza season, in which 64.1% of circulating influenza viruses were type B strains with a complete vaccine mismatch (Table 3) .
| Taiwan
Thirteen studies conducted between 1995 and 2012 were identified for Taiwan (Table 2) . Five articles reported data in children, and no studies specifically reported on influenza B in adults. All studies con- 76% of the circulating influenza viruses were type B (Table 3) . 44, 73 The 
| Thailand

| Distribution of influenza B by age group
There were 22 articles that provided information on influenza B in different age groups (Table 4 ). The grouping of ages differed between studies which hinders easy comparisons.
In studies reporting age-stratified data, the proportions of influenza caused by influenza type B were higher among children aged between 1 and 10 years than in older age gro ups. 23, 30, 46, 50, 51, 56, 58, 59, [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] In 17 studies using comparable age strata, between 10.9% and 90% of all influenza B cases were detected in children aged <10 years (Table 4) . Considering 18 studies with a cutoff at <20 years of age, in all but one study, more One study from Victoria, Australia, estimated the rate of notified laboratory-confirmed influenza cases (reported in 2012 to the Victorian Department of Health) to be 154/100 000 persons in those aged 0-4 years, 137/100 000 in those aged ≥65 years, and 61-90/100 000 for other age groups. 30 The proportion of notified cases that were influenza B was highest in those aged 5-15 years (30.3%) and 15-29 years (20.5%), followed by those aged 30-49 years (14.2%), 50-64 years (10.7%), <5 years (8.7%), and ≥65 years (8.6%).
| Circulating influenza B strains
The available data indicate that both Yamagata and Victoria influenza type B lineages have circulated in Asia-Pacific countries during the last decade. The ratio of Yamagata to Victoria strains varied from year to year, and sometimes differed between countries in the northern and Southern Hemispheres within the same season (Table 3) . Furthermore, the predominant lineage was not always the same in countries within the same region. For example, in 2012, an influenza type B Victoria strain predominated in Australia, whereas a Yamagata strain predominated in New Zealand (Table 3) . In 2007, a Yamagata strain predominated in Malaysia, whereas a Victoria strain predominated in Indonesia ( In countries that provided seasonal numerical estimates of lineage distribution, the majority of mismatched seasons in each country were significant or complete mismatches (Tables 3 and 5 ). In mismatched years without precise estimates of the distribution of type B lineages, the available descriptions suggest that all of the mismatches were likely to be significant or complete. results from co-circulation of several types/lineages, the degree of antigenic drift, combined with the hosts' immune status, which together ensure the continuing ability of the virus to cause illness. 9 Significant or complete mismatches between the circulating and trivalent vaccine type B strain were observed on numerous occasions in countries with available data. Our study was not designed to quantify the possible public health implications in seasons where vaccine mismatch existed. Influenza vaccine efficacy is reduced when there is a mismatch between vaccine and circulating strains, 14, 86 suggesting that a mismatch season is likely to be associated with a higher clinical disease burden.
| DISCUSSION
Influenza B causes similar morbidity as influenza A. 87 In mismatch seasons, hospitalization due to influenza type B can exceed that due to influenza A in all age groups. 71 The available data suggest that consistent with observations in other regions, 7, 9 in the Asia-Pacific region, influenza B occurs more frequently in children aged between 1 and 10 years than in other age groups and causes more severe disease in this age group than influenza A. 88 Evidence suggests differences in the age distribution of patients infected with the B/Yamagata or B/Victoria lineages, with the latter appearing to be more frequently identified in younger age groups. [89] [90] [91] [92] [93] Although developed countries such as USA, Japan, Australia, and some European countries. As younger children have a globally higher probability of being infected with the influenza B viruses, this group is most likely to benefit more from a quadrivalent vaccine containing both B lineages due to the frequent mismatch and co-circulation of both influenza B lineages.
The articles included in this review varied with respect to their design, population characteristics (eg, age range, mild vs severe cases), the illness definition selected for study (specific vs non-specific diagnoses), the laboratory methods used to detect influenza, and the methods of case surveillance (population-based, laboratory-based, hospital or emergency department-based, sentinel general practice). Therefore, the results of individual studies cannot be easily compared and are unlikely to be broadly representative. In some articles, data were not stratified per year, and only an average proportion of influenza type B over the study period could be obtained. In many studies, proportions of influenza B among any laboratory-confirmed influenza cases were only available within a specified population. Most information was retrieved for China, Australia, South Korea, and Taiwan, but four articles or fewer were identified for Laos, Myanmar, the Philippines, and Papua New Guinea.
This review has identified important knowledge gaps within the region. In several countries, the epidemiology of influenza and influenza type B is not well described, little is known about the age groups collecting the data, the supervision of the analysis, and the interpretation of data. All authors were involved in the development of this manuscript, had full access to the data, and gave final approval before submission.
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